Don’t fight Childhood acute lymphoblastic leukemia alone.Find your community on the free RareGuru App.
Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become lymphoblasts, B lymphocytes, or T lymphocytes. These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include combination chemotherapy, targeted therapy, and/or stem cell transplant.
On August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.
Source: GARD Last updated on 05-01-20
Even though childhood acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, it is still considered a rare disease. In the Unites States, a disease is defined as rare when it affects fewer than 200,000 people at a given time.
There are approximately 2,900 children and adolescents younger than 20 years of age diagnosed with ALL each year in the United States. Over the past 25 years, there has been a gradual increase in the incidence of ALL. The incidence is highest among children age 2 to 3 years. It appears to be highest in Hispanic children, and is substantially higher in white children than in black children.
Last updated on 05-01-20
The long-term outlook (prognosis) for people with childhood acute lymphoblastic leukemia (ALL), including the potential for long-term cure, depends on the severity of the condition, laboratory features, and treatment. Factors that may affect prognosis include the age and white blood cell count at the time of diagnosis; biologic characteristics of the leukemia cells; response to chemotherapy; and the amount of cancer cells that remain during treatment or remission. This information can be used to assess the risk for each affected person.
Overall, the cure rate for childhood ALL is more than 80%. Five-year survival rates for children rose to 90% from 2000-2005. Improvement in survival has been seen for all age groups of children, except for infants younger than 1 year (who have a poor outcome). In low-income countries, treatment results have been less encouraging.
Potential acute complications can include tumor lysis syndrome, renal failure, sepsis, bleeding, thrombosis (development of a blood clot), inflammation of the cecum (typhlitis), neuropathy, encephalopathy, or seizures.
Lifelong follow-up is necessary because survivors may have late complications from the treatment, such as secondary malignancy, short stature, growth hormone deficiency, learning disabilities, or cognitive defects.
Last updated on 05-01-20
Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!